List of Excipients in Branded Drug UP AND UP ANTI DIARRHEAL

Generic Drugs Containing UP AND UP ANTI DIARRHEAL

Company	Ingredient	NDC	Excipient
Target Corporation	loperamide hydrochloride	11673-224	ANHYDROUS LACTOSE
Target Corporation	loperamide hydrochloride	11673-224	CARNAUBA WAX
Target Corporation	loperamide hydrochloride	11673-224	CELLULOSE, MICROCRYSTALLINE
Target Corporation	loperamide hydrochloride	11673-224	D&C YELLOW NO. 10 ALUMINUM LAKE

What are the Most Frequently-Used Excipients in UP AND UP ANTI DIARRHEAL?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	ANHYDROUS LACTOSE
1	CARBOXYMETHYLCELLULOSE SODIUM
1	CARNAUBA WAX

Up & Up Anti-Diarrheal Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Up & Up Anti-Diarrheal is a private-label over-the-counter loperamide hydrochloride product sold through Target. Its commercial position depends less on active-ingredient differentiation than on low-cost manufacturing, reliable tablet performance, package convenience, and extensions into liquid, chewable, travel, and symptom-specific formats. Loperamide hydrochloride is an established OTC active ingredient with limited active-ingredient patent risk. The strongest opportunities are formulation execution, supply-chain efficiency, packaging, and retailer-specific product segmentation.

What active ingredient and dosage form does Up & Up Anti-Diarrheal use?

Up & Up Anti-Diarrheal is generally marketed as loperamide hydrochloride 2 mg, the same active ingredient and strength used in leading loperamide products such as Imodium A-D. The product is intended for temporary control of diarrhea and is labeled for adults and children age 6 and older, subject to the applicable product labeling.[1][2]

Product attribute	Up & Up Anti-Diarrheal
Brand owner	Target private-label Up & Up
Active ingredient	Loperamide hydrochloride
Typical strength	2 mg per dosage unit
Therapeutic category	OTC antidiarrheal
Regulatory pathway	OTC monograph or monograph-compliant drug product
Primary competitive reference	Imodium A-D
Likely dosage forms	Tablets, caplets, or capsules depending on SKU
Prescription requirement	No
Primary commercial channel	Target stores and Target.com

Loperamide acts locally in the gastrointestinal tract and reduces intestinal motility. It is not intended for use in certain cases involving bloody stool, high fever, antibiotic-associated colitis, or suspected infectious diarrhea. The label also limits daily dosing because excessive use can cause serious cardiac effects.[1][2]

What excipients are likely used in Up & Up Anti-Diarrheal?

The precise inactive-ingredient profile depends on the individual Up & Up SKU and dosage form. Public product labels should be treated as the controlling source for a particular package configuration. Standard immediate-release loperamide tablets and caplets commonly use excipients selected for compressibility, rapid disintegration, lubrication, and physical stability.

Potential excipient classes include:

Excipient function	Common candidate excipients	Commercial purpose
Filler and compressibility	Microcrystalline cellulose, dibasic calcium phosphate, lactose, starch	Supports tablet weight, hardness, and manufacturing yield
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid breakup after ingestion
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet integrity
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Improves appearance, handling, swallowability, and product identification
Capsule shell	Gelatin or hypromellose	Enables capsule dosage forms
Taste modification	Sweeteners, flavors, film coating	Relevant to chewables and liquids
Liquid vehicle	Purified water, glycerin, sorbitol, preservatives	Supports oral liquid delivery

A low-cost private-label product typically favors well-established excipients with broad regulatory acceptance and multiple qualified suppliers. The formulation objective is usually not to create a new pharmacologic profile. It is to achieve consistent assay, disintegration, dissolution, appearance, and shelf life at the lowest delivered cost.

How should the excipient strategy be optimized?

Immediate-release tablet platform

The base platform should use a robust direct-compression or wet-granulation process. Microcrystalline cellulose combined with a superdisintegrant can support rapid tablet breakup without requiring an expensive specialized delivery system.

The formulation should target:

• Rapid disintegration under pharmacopeial testing.
• Consistent dissolution across commercial-scale batches.
• Low tablet friability.
• Adequate hardness for high-volume retail handling.
• Low sensitivity to humidity.
• Minimal sticking and picking during compression.
• Stable color and coating appearance.
• Compatibility with high-speed packaging.

A direct-compression formulation may lower processing costs, but it can be more sensitive to powder-flow variation and lubricant overmixing. Wet granulation may improve content uniformity and tablet robustness but adds processing time, energy consumption, and validation burden.

Film-coated caplets

A film-coated caplet can command a modest consumer preference advantage over an uncoated tablet because it is easier to swallow and less susceptible to chipping. The coating also allows product differentiation through color, imprinting, and package identity.

For Up & Up, a thin hypromellose-based coating is likely to be more commercially efficient than a thick functional coating. A high-build coating would increase cycle time and material usage without providing a meaningful therapeutic benefit.

Chewable dosage form

A chewable loperamide product would create a more defensible consumer proposition than a standard tablet. The principal formulation issues are bitterness, aftertaste, mouthfeel, and dose uniformity.

Potential approaches include:

• High-intensity sweeteners combined with polyols.
• Flavor systems that suppress bitterness rather than simply adding sweetness.
• Taste-masking coating or granulation.
• Lower-density chewable matrix.
• Moisture-barrier packaging to protect texture.

The commercial risk is that loperamide’s bitter taste may require a more complex taste-masking system than a conventional analgesic or antacid. Polyols can also create gastrointestinal tolerance concerns if used at high levels, which is commercially counterproductive for an antidiarrheal product.

Oral liquid

A liquid formulation would address consumers who cannot swallow tablets, but it has higher formulation and packaging complexity. Key requirements include:

• Uniform suspension or solution behavior.
• Preservative effectiveness.
• Accurate dosing with a cup or oral syringe.
• Child-resistant packaging.
• Protection against microbial contamination.
• Stable viscosity and pourability across temperature ranges.

The liquid format may produce higher gross margins but also increases unit cost, packaging loss, shipping weight, and quality-control requirements. It is better suited to pediatric and family positioning than to the lowest-price adult segment.

What formulation patents could protect an Up & Up product?

The loperamide active ingredient is mature, and broad composition-of-matter protection is not a meaningful barrier for a conventional OTC product. The relevant IP categories would be narrower:

1. A taste-masked loperamide composition.
2. A rapidly disintegrating tablet.
3. A chewable matrix with improved mouthfeel.
4. A stable oral liquid or suspension.
5. A specific multiparticulate or orally disintegrating dosage form.
6. A packaging system that limits misuse or improves dose control.
7. A manufacturing process that improves content uniformity or coating efficiency.

A conventional 2 mg loperamide tablet using standard excipients is unlikely to support strong standalone patent protection. Many basic combinations of microcrystalline cellulose, a superdisintegrant, magnesium stearate, and a film coat would face substantial novelty and obviousness challenges.

Commercially meaningful protection would require a measurable technical effect, such as:

• A material reduction in bitterness.
• Faster onset supported by dissolution data.
• Improved stability under elevated humidity.
• Better dose uniformity in a low-dose formulation.
• Reduced abuse potential.
• A distinctive delivery system with clinical or consumer utility.

Patent protection is more likely to be valuable for a differentiated platform than for the current standard tablet.

What is the FDA regulatory status of Up & Up Anti-Diarrheal?

Loperamide hydrochloride is an established OTC antidiarrheal active ingredient regulated under the FDA’s nonprescription drug framework. The applicable OTC monograph identifies loperamide hydrochloride as an antidiarrheal active ingredient at recognized dosing levels and labeling conditions.[3]

The principal regulatory requirements include:

• Compliance with the applicable OTC monograph.
• Drug Facts labeling.
• cGMP manufacturing.
• Finished-product identity, strength, quality, and purity testing.
• Stability data supporting the labeled shelf life.
• Child-resistant packaging where required.
• Adverse-event monitoring.
• Label controls addressing maximum daily dose and misuse risks.

Because the product is an OTC private-label drug, the regulatory burden remains with the responsible manufacturer or drug establishment identified in the product documentation. Target’s retail branding does not eliminate the need for a compliant drug listing, manufacturing controls, and quality systems.

What is the Orange Book status of Up & Up Anti-Diarrheal?

A conventional OTC loperamide product is not generally dependent on an Orange Book-listed innovator patent estate in the way a prescription drug is. The Orange Book primarily addresses approved prescription and certain approved nonprescription drug products with therapeutic-equivalence listings.[4]

For Up & Up Anti-Diarrheal, the practical IP analysis is therefore different:

IP issue	Risk assessment
Loperamide composition-of-matter patent	Low for a mature OTC product
Basic 2 mg tablet formulation	Low to moderate, depending on third-party claims
Branded product trademark	Relevant to Target and brand owners
Taste-masked or chewable formulation	Potentially moderate
Oral liquid formulation	Potentially moderate
Manufacturing know-how	Moderate if process-specific and difficult to replicate
Orange Book patent listing	Not the primary commercial barrier
Paragraph IV exposure	Limited relevance unless a listed drug or patent-linked product is involved

Paragraph IV litigation is not the central entry mechanism for a standard private-label loperamide tablet. Competitive entry generally depends on OTC regulatory compliance, manufacturing capacity, retailer authorization, and product economics rather than on invalidating an active Orange Book patent.

When does Up & Up Anti-Diarrheal lose exclusivity?

Up & Up Anti-Diarrheal does not have meaningful exclusivity based on the loperamide active ingredient. Its commercial exclusivity is retailer-based and brand-based rather than patent-based.

Target can preserve differentiation through:

• Exclusive shelf placement.
• Private-label pricing.
• Package-count variations.
• Store-brand trust.
• Online search ranking.
• Bundled travel or family-care offerings.
• Product formats not carried by competing retailers.

The product remains exposed to Walmart’s Equate, CVS Health, Walgreens, Rite Aid, Amazon Basic Care, Dollar General, and other private-label loperamide products. Generic substitution is not the main issue because the OTC category is already populated by competing store brands.

What commercial opportunities exist for excipient-led product extensions?

Lower-cost standard tablet

The highest-probability opportunity is a cost-optimized tablet using dual-source excipients and a simplified coating system. Savings can come from:

• Direct compression.
• Reduced coating weight.
• Fewer excipient suppliers.
• Larger batch sizes.
• Standardized tablet tooling.
• Blister or bottle packaging selected by channel economics.

This approach supports price leadership but has limited consumer differentiation.

Rapid-dissolve tablet

A fast-disintegrating tablet could be marketed around convenience, particularly for travel and urgent symptom management. The product should avoid unsupported claims of faster clinical action unless the formulation has suitable evidence. Dissolution improvement alone does not automatically establish faster therapeutic onset.

Potential excipient tools include crospovidone, croscarmellose sodium, porous carriers, and orally disintegrating tablet technologies. The principal risks are friability, moisture sensitivity, and unpleasant mouthfeel.

Chewable loperamide

A chewable format offers a stronger commercial platform. It could target:

• Travelers.
• Consumers who avoid swallowing pills.
• Adults seeking a portable product.
• Family first-aid kits.

Taste masking would determine product acceptance. The package should use unit-dose blisters or a controlled-dispensing bottle to reduce accidental overuse.

Liquid and pediatric-oriented products

An oral liquid could expand household penetration, but the product requires strict age labeling and dosing controls. Loperamide use in young children is restricted, and the label must not imply broad pediatric suitability. The commercial opportunity is therefore narrower than for common pediatric fever reducers.

Combination products

A loperamide combination product could pair the active ingredient with an electrolyte, probiotic, or gas-relief component. Each combination increases regulatory, labeling, stability, and clinical-substantiation complexity. A combination may also create additional safety concerns or confuse consumers about appropriate use.

For a mass retailer, a single-ingredient product with a clear Drug Facts label is more likely to produce reliable returns than a complex combination.

Which companies challenge Up & Up Anti-Diarrheal commercially?

The main competitive set consists of branded loperamide products and retailer private labels.

Competitor	Positioning	Primary competitive pressure
Imodium A-D	National brand	Brand recognition and format breadth
Equate	Walmart private label	Price and scale
CVS Health	Pharmacy private label	Store traffic and pharmacy trust
Walgreens	Pharmacy private label	Retail availability
Amazon Basic Care	E-commerce private label	Online price transparency
Rite Aid	Pharmacy private label	Regional retail presence
Dollar-store brands	Value segment	Lowest shelf price

The competitive moat for Up & Up is Target’s retail ecosystem, not formulation exclusivity. Excipient innovation is commercially useful only when it creates a visible consumer benefit or lowers cost without reducing quality.

How strong is the patent estate for Up & Up Anti-Diarrheal?

The likely patent estate is weak for the conventional product and potentially stronger for differentiated extensions.

Product strategy	Patent strength	Commercial value
Standard 2 mg tablet	Low	Cost and distribution advantage
Film-coated caplet	Low	Moderate usability benefit
Rapid-disintegrating tablet	Low to moderate	Convenience differentiation
Taste-masked chewable	Moderate	Potentially high if performance is proven
Stable oral liquid	Moderate	Family and accessibility expansion
Abuse-deterrent formulation	Moderate to high	Regulatory and safety differentiation, but costly
Proprietary packaging	Low to moderate	Retail and safety benefit
Novel manufacturing process	Moderate	Supplier and quality advantage

Trade secrets may be more valuable than patents for a conventional SKU. Granulation endpoints, coating parameters, taste-masking ratios, and supplier qualification data can reduce manufacturing variability and support stable margins. Those assets are difficult for competitors to identify from the finished package.

What generic launch risks exist?

A new loperamide product could reach the market without confronting major composition-of-matter barriers, but launch risks remain:

• Failure to meet dissolution or assay specifications.
• Taste complaints for chewable products.
• Excessive tablet friability.
• Packaging-related moisture ingress.
• Supply shortages for critical excipients.
• Labeling errors involving age or maximum dose.
• Retailer quality audits.
• Adverse-event scrutiny related to misuse.
• Price compression from multiple private-label competitors.
• Product recalls caused by manufacturing deviations.

The most defensible launch plan is a two-stage platform: first, a low-cost immediate-release tablet; second, a differentiated chewable or rapid-dissolve format after consumer and stability testing.

Key Takeaways

• Up & Up Anti-Diarrheal is a Target private-label loperamide hydrochloride product, typically supplied at 2 mg per dosage unit.
• Standard tablet excipients are unlikely to create strong patent protection.
• The highest-value excipient opportunities are taste masking, rapid disintegration, moisture protection, and liquid-dose control.
• Loperamide’s commercial exclusivity is retailer-driven, not primarily patent-driven.
• Paragraph IV litigation and Orange Book patent barriers are limited for a conventional OTC loperamide product.
• A standard tablet supports cost leadership; a chewable or rapid-dissolve product offers greater differentiation.
• Manufacturing know-how and supplier qualification may have more practical value than broad formulation patents.
• Target’s main commercial exposure is price competition from Equate, national brands, pharmacy private labels, and e-commerce products.
• No public product-level revenue figure can be assigned to Up & Up Anti-Diarrheal without Target’s SKU-level sales disclosure.

FAQs

Is loperamide hydrochloride still patent protected?

Broad active-ingredient protection for loperamide hydrochloride is not the principal market barrier for current OTC products. Any meaningful protection would usually relate to a specific formulation, dosage form, manufacturing process, or packaging system.

Can a company patent a loperamide chewable tablet?

Yes, but a patent would need to claim a novel and non-obvious formulation or process. Taste masking, stability, dissolution, and mouthfeel data would be important to support commercial value.

Which excipient is best for rapid loperamide tablet disintegration?

Croscarmellose sodium, crospovidone, and sodium starch glycolate are common candidates. Selection depends on tablet hardness, lubricant level, compression force, moisture exposure, and dissolution performance.

Is an Up & Up loperamide product therapeutically equivalent to Imodium A-D?

Products using the same active ingredient and strength can be therapeutically comparable when manufactured and labeled in accordance with applicable FDA requirements. Brand equivalence does not mean identical inactive ingredients, appearance, packaging, or consumer experience.

What is the most attractive new dosage form for loperamide?

A taste-masked chewable tablet is the strongest differentiation opportunity, while a rapid-disintegrating tablet is generally easier to manufacture and commercialize. An oral liquid expands accessibility but carries higher stability, packaging, and dosing-control costs.

References

1. National Library of Medicine. (n.d.). DailyMed: Loperamide hydrochloride drug labels. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Loperamide hydrochloride drug facts and safety information. https://www.fda.gov/

3. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 335: Antidiarrheal products for over-the-counter human use. https://www.ecfr.gov/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/ 񟿿